Full Press Release Details
Natural killer cells continuously patrol the human body, swiftly eliminating viruses and cancer cells, like sharks in prey-laden waters. Several biotech companies are harnessing the power of these innate immune crusaders in oncology and autoimmune diseases, potentially positioning them as a strong competitor to CAR-T cell therapies.
“The advantage of NK cells over a T-cell approach is that NK cells can kill the target cell without causing that runaway cytokine release syndrome,” said Dr. Fred Aslan, president and CEO of Artiva Biotherapeutics. In addition to potential safety advantages, NK cell therapies could disrupt the market by offering a less costly off-the-shelf option that speeds patient access.
Read the full article at PharmaVoice.